[ad_1]
Alzheimer's disease is a neurodegenerative disorder, progressive and irreversible. Alzheimer's disease is caused by abnormal functioning of brain cells, that is, failure of synaptic transmission, resulting in loss of cognitive function. Signs and symptoms of Alzheimer's disease include memory loss, insomnia, repetitive movements, restlessness, anxiety, depression, and loss of reasoning ability. Any memory and mental functioning can be lost in the advanced stages of the disease. Alzheimer's disease can lead to death. According to the National Institute of Aging, Alzheimer's is the most common form of dementia.
North America dominates the global market for Alzheimer's disease treatments because of the large number of aging people. Asia, followed by Europe, is expected to post strong growth rates over the next five years in the global market for Alzheimer's disease treatments. China and India are expected to be the fastest growing therapeutic drug markets for Alzheimer's disease in the Asia-Pacific region. R & D investments, large numbers of patients and improved healthcare infrastructure are among the main drivers of the Alzheimer's disease market in emerging countries.
The recent use of therapeutics for Alzheimer's disease has increased due to the increasing prevalence of Alzheimer's disease. The increase in the geriatric population, the increase in health care expenditures and the increase in public funds are among the main factors in the growth of the global market for Alzheimer's disease treatments. In addition, heightened awareness of health care and new diagnostic technologies for Alzheimer's disease are also fueling the growth of the global Alzheimer's disease market. However, strict regulation and a long approval period for Alzheimer's disease treatments and the expiry of several patented medicines are among the main factors holding back the growth of the global market for Alzheimer's patients.
Sample Request: https://www.persistencemarketresearch.com/samples/3401
The increase in R & D investments of biopharmaceutical companies would lead to a growth in the market for drugs for the treatment of Alzheimer's disease in Asia. In addition, the innovation of new drugs to treat, slow down and prevent Alzheimer's disease and the early diagnosis of Alzheimer's disease could create opportunities for the global market for Alzheimer's disease treatments. F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer, Inc., Novartis AG., Eisai Co., Ltd., Actavis, Daiichi Sankyo, Transtech Pharma and H. Lundbeck A / S.
Key points discussed in the report
- The report segments the market according to types, application, products, technology, and so on. (depending on the case)
- The report covers geographical segmentation
- The report provides market size and forecasts for different segments and geographic areas for the period 2010 to 2020.
- The report provides company profiles of some of the leading companies in the market.
- The report also provides marketers with five market badyzes.
Source link
